PRPSAP2: A Promising Drug Target and Biomarker for Parkinson's disease

Target Name: PRPSAP2

NCBI ID: G5636

PRPSAP2

Other Name(s): PAP41 | phosphoribosyl pyrophosphate synthetase associated protein 2 | KPRB_HUMAN | PRPP synthase-associated protein 2 | 41 kDa phosphoribosypyrophosphate synthetase-associated protein | Phosphoribosyl pyrophosphate synthetase associated protein 2, transcript variant 1 | Phosphoribosyl pyrophosphate synthase-associated protein 2 (isoform 1) | PRPSAP2 variant 1 | Phosphoribosyl pyrophosphate synthase-associated protein 2

PRPSAP2: A Promising Drug Target and Biomarker for Parkinson's disease

Introduction

Parkinson's disease is a neurodegenerative disease characterized by the degeneration of dopaminergic neurons in the substantia nigra area, which seriously affects the patient's quality of life and health. The pathogenesis of Parkinson's disease is not fully understood, but according to research, neuronal degeneration, abnormal neuronal connections, and neuron loss are the main causes of Parkinson's disease. Therefore, finding new therapeutic targets and biomarkers is of great clinical significance.

PRPSAP2: a drug target worthy of attention

PRPSAP2 is a familial protein and a member of the phosphatidylserine-binding protein (PSP) family. The PSP family plays a key role in the structure and function of cell membranes and participates in many important biological processes. In recent years, researchers have found that PRPSAP2 is up-regulated in patients with Parkinson's disease and plays an important role in the pathogenesis of Parkinson's disease.

First, studies have shown that PRPSAP2 is closely related to neuronal loss in patients with Parkinson's disease. Loss of PRPSAP2 leads to increased neuronal loss, further aggravating the condition of Parkinson's disease patients. In addition, overexpression of PRPSAP2 may also be related to abnormalities in neuronal synapses in patients with Parkinson's disease.

Second, PRPSAP2 is closely related to the activity of dopaminergic neurons in Parkinson's disease patients. Dopaminergic neurons are often damaged in patients with Parkinson's disease, and PRPSAP2, as a protein related to dopaminergic neuron activity, may become a potential target for the treatment of Parkinson's disease.

Third, the expression level of PRPSAP2 is positively correlated with the number of dopaminergic neurons in the substantia nigra in patients with Parkinson's disease. This means that the reduction of PRPSAP2 may lead to the reduction of dopaminergic neurons in the substantia nigra area of 鈥嬧?媝atients with Parkinson's disease, thereby affecting the condition of patients with Parkinson's disease.

Finally, research shows that loss of PRPSAP2 leads to exaggerated neuronal loss and neuronal synaptic abnormalities in Parkinson's disease patients. These pathological changes are highly correlated with the clinical manifestations and pathological characteristics of Parkinson's disease.

In summary, PRPSAP2 is a potential drug target, especially in the field of Parkinson's disease. Future studies can further confirm the role of PRPSAP2 in Parkinson's disease and provide new treatment options for Parkinson's disease patients.

Protein Name: Phosphoribosyl Pyrophosphate Synthetase Associated Protein 2

Functions: Seems to play a negative regulatory role in 5-phosphoribose 1-diphosphate synthesis

The "PRPSAP2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PRPSAP2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets